Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Syros Pharmaceuticals (SYRS)
NASDAQ:SYRS
RESEARCH TOOLSreports
Holding SYRS?
Track your performance easily
SYRS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.18 - $8.17
Previous Close$0.27
Volume1.73M
Average Volume (3M)8.16M
Market Cap
$7.29M
Enterprise Value$9.24M
Total Cash (Recent Filing)$58.27M
Total Debt (Recent Filing)$60.23M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Mar 06, 2025EPS Estimate
-$0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.03
Shares Outstanding26,832,457
10 Day Avg. Volume46,965,183
30 Day Avg. Volume8,155,029
Standard Deviation0.33
R-Squared0.06
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)-0.71
Price to Sales (P/S)19.19
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue23.87
Enterprise Value/Gross Profit0.93
Enterprise Value/Ebitda-0.10
Forecast
1Y Price Target
$3.00Price Target Upside1004.97% Upside
Rating ConsensusHold
Number of Analyst Covering5
Syros Pharmaceuticals News
PremiumCompany Announcements
Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe SELECT-MDS-1 Phase 3 trial has successfully completed enrollment for its primary endpoint analysis, paving the way for future regulatory submissions.
Market PotentialTamibarotene presents a significant commercial opportunity in RARA-positive HR-MDS, with a market potential estimated at $1.6 billion.
Therapeutic InnovationTamibarotene is positioned to become the first targeted therapy for patients with RARA overexpression, addressing a critical unmet need in the treatment landscape.
Bears Say
Clinical Trial FailureThe Phase 3 SELECT-MDS-1 trial did not achieve its primary endpoint of complete response rate, leading to the decision to remove tamibarotene from valuation.
Financial And Loan Default RiskThe failure to meet the primary endpoint in the SELECT-MDS-1 trial triggers an event of default under the secured loan agreement with Oxford Finance LLC.
Stock Valuation And Market ReactionThe stock traded down about 86% in the aftermarket, reflecting a significant decline in valuation.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SYRS FAQ
What was Syros Pharmaceuticals’s price range in the past 12 months?
Syros Pharmaceuticals lowest stock price was $0.18 and its highest was $8.17 in the past 12 months.
What is Syros Pharmaceuticals’s market cap?
Currently, no data Available
When is Syros Pharmaceuticals’s upcoming earnings report date?
Syros Pharmaceuticals’s upcoming earnings report date is Mar 06, 2025 which is in 69 days.
How were Syros Pharmaceuticals’s earnings last quarter?
Syros Pharmaceuticals released its earnings results on Oct 31, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.676 by $0.516.
Is Syros Pharmaceuticals overvalued?
According to Wall Street analysts Syros Pharmaceuticals’s price is currently Undervalued.
Does Syros Pharmaceuticals pay dividends?
Syros Pharmaceuticals does not currently pay dividends.
What is Syros Pharmaceuticals’s EPS estimate?
Syros Pharmaceuticals’s EPS estimate is -$0.69.
How many shares outstanding does Syros Pharmaceuticals have?
Syros Pharmaceuticals has 26,832,457 shares outstanding.
What happened to Syros Pharmaceuticals’s price movement after its last earnings report?
Syros Pharmaceuticals reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.676. Following the earnings report the stock price went up 0.398%.
Which hedge fund is a major shareholder of Syros Pharmaceuticals?
Among the largest hedge funds holding Syros Pharmaceuticals’s share is Flagship Pioneering Inc.. It holds Syros Pharmaceuticals’s shares valued at 3M.
---
Company Description
Syros Pharmaceuticals
Syros Pharmaceuticals, Inc. engages in the development of novel gene control therapies for cancer and other diseases. It has developed a proprietary platform that is designed to systematically and efficiently analyse unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. The firm focuses on developing treatments for cancer and immune mediated diseases and is building a pipeline of gene control medicines. The company was founded by Richard A. Young, Nathanael S. Gray and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
---
SYRS Earnings Call
Q3 2024
0:00 / 0:00
---
SYRS Stock 12 Month Forecast
Average Price Target
$3.00
▲(1004.97% Upside)
Technical Analysis
Mersana Therapeutics
―
Adaptimmune Therapeutics
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Best Analysts Covering SYRS
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-54.70%
reiterated a buy rating 2 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -54.70% per trade.
---